NIKKEI 225
38,085.82 -728.74 (-1.88%) HANG SENG
18,009.15 +67.37 (+0.38%) CRUDE OIL
78.14 -0.31 (-0.40%) GOLD FUTURES
2,335.50 -13.60 (-0.58%) DOW
38,589.16 -57.94 (-0.15%) Bitcoin GBP
52,348.36 +146.63 (+0.28%)
APLS Oct 2024 45.000 call
| Previous close | 6.39 |
| Open | 6.39 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 45.00 |
| Expiry date | 2024-10-18 |
| Day's range | 6.39 - 6.39 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksApellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study
Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.
GlobeNewswireSYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
SYFOVRE is the only approved GA treatment to demonstrate a visual function benefit in a prespecified endpointData presented at the Clinical Trials at the Summit Meeting WALTHAM, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that SYFOVRE® (pegcetacoplan injection) preserved visual function at 36 months in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). These positive data from the GALE long-term ext
ZacksWhy Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report?
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
